AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 23848405
Drug: 2 μg.kg(‐1)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 μg.kg(‐1) intranasal dexmedetomidine with 3 mg.kg(‐1) oral ketamine (Group 3)
Trial: 23848405
Drug: 2 μg.kg(‐1)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 μg.kg(‐1) intranasal dexmedetomidine with 5 mg.kg(‐1) oral ketamine (Group 4)
Trial: 8914773
Drug: HIV‐1MN recombinant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HIV‐1MN recombinant gp120 (rgp120) vaccine
Trial: 8914773
Drug: HIV‐1MN recombinant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HIV‐1MN recombinant gp120 (rgp120) vaccine with HIV‐1IIIB rgp120 vaccine
Trial: 6881177
Drug: Corticosteroid treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Corticosteroid treatment (intravenous bolus of methylprednisolone followed by an eight-day tapering course of oral methylprednisolone starting at 32 mg twice a day)
Trial: 29232351
Drug: Intraurethral 2%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraurethral 2% lidocaine jelly administered via Uro‐Jet, 5 minutes before TUBC.
Trial: 24055512
Drug: Vacuum-assisted wound
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vacuum-assisted wound closure (VAC) therapy
Trial: 24055512
Drug: Alginate (Sorbalgon)
DrugBank: Alginic acid (DB13518)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alginate (Sorbalgon) therapy
Trial: 24055512
Drug: Alginate therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alginate therapy
Trial: 22429343
Drug: 1000 mg
RxNorm normalized name: bran 1000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1000 mg vitamin C plus 10 mg zinc
Trial: 19076086
Drug: Multicenter randomized
RxNorm normalized name: jojoba oil, randomized
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multicenter randomized trials and novel classes of drugs and interventional catheter technologies
Trial: 15919685
Drug: Adjuvant chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant chemotherapy (non-anthracycline-based)
Trial: 10889132
Drug: Use of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Use of angiotensin-converting enzyme inhibitors
Trial: 8821417
Drug: N-acetylcysteine (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: N-acetylcysteine (100 mg/kg body weight)
Trial: 8821417
Drug: Streptokinase without
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Streptokinase without further treatment
Trial: 1431255
Drug: HA-1A (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HA-1A (100 mg intravenous single dose)
Trial: 31050833
Drug: Aspirin at
RxNorm normalized name: rose bengal AT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin at doses below 75 mg daily
Trial: 31050833
Drug: Direct oral
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Direct oral anticoagulants at doses 1/4 of those recommended for atrial fibrillation
Trial: 31050833
Drug: Lower doses
RxNorm normalized name: flowers
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lower doses of antithrombotics than currently recommended
Trial: 24819710
Drug: Stepwise protocol
RxNorm normalized name: levonorgestrel
DrugBank: Levonorgestrel (DB00367)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Stepwise protocol of treating pain (SPTP) with acetaminophen, morphine, buprenorphine transdermal patch, and pregabalin for 8 weeks
Trial: 20959429
Drug: BIBN4096BS (olcegepant)
RxNorm normalized name: Olcegepant
DrugBank: Olcegepant (DB04869)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BIBN4096BS (olcegepant) 10 mg
Trial: 10688397
Drug: Tobramycin solution
RxNorm normalized name: Tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Tobramycin solution for inhalation (TOBI) for 24 weeks
Trial: 9778488
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose inhaled fluticasone propionate (250 mcg bd)
Trial: 8105814
Drug: Early neuroleptic
RxNorm normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Early neuroleptic intervention treatment
Trial: 3536947
Drug: Preincisional presternal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preincisional presternal antibiotic infiltration (2%)
Trial: 27133971
Drug: Universal pre-procedural
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Universal pre-procedural indometacin (100 mg rectal indometacin within 30 min before ERCP)
Trial: 24184292
Drug: No light
RxNorm normalized name: OCTINOXATE 67 mg in 1 mL / TITANIUM DIOXIDE 18 mg in 1 mL TOPICAL LOTION [Valentino Very Valentino Light Lasting Perfecting Foundation Broad Spectrum SPF 26 Sunscreen]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No light therapy (after Luminette® use)
Trial: 18378381
Drug: No statin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No statin therapy (Control group)
Trial: 16685353
Drug: Niuhuangjiedu tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Niuhuangjiedu tablets (control)
Trial: 14533985
Drug: rhu‐GM‐CSF (125mg/M(2))
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rhu‐GM‐CSF (125mg/M(2)) injected subcutaneously twice weekly for four weeks
Trial: 10943575
Drug: Ethinylestradiol/drospirenone (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ethinylestradiol/drospirenone (30 microg ethinylestradiol and 3 mg drospirenone)
Trial: 1544778
Drug: Acetazolamide 500
RxNorm normalized name: acetazolamide 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetazolamide 500 mg vs Placebo
Trial: 3534203
Drug: Amoxicillin plus
RxNorm normalized name: Amoxicillin
DrugBank: Amoxicillin (DB01060)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amoxicillin plus clavulanate (40 mg/kg amoxicillin plus 10 mg/kg clavulanate, total daily doses in three divided doses)
Trial: 3534203
Drug: Cefaclor (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefaclor (40 mg/kg)
Trial: 27454547
Drug: Lurasidone 20
RxNorm normalized name: lurasidone 20 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lurasidone 20 mg/d
Trial: 7929868
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg of controlled-release metoprolol
Trial: 7929868
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg of atenolol
Trial: 22810476
Drug: Perianal administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Perianal administration of 0.4% nitroglycerin ointment (375 mg containing 1.5 mg glyceryl trinitrate), applied every 12 hours for 8 weeks
Trial: 22810476
Drug: Endoanal administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Endoanal administration of 0.4% nitroglycerin ointment (375 mg containing 1.5 mg glyceryl trinitrate), applied every 12 hours for 8 weeks
Trial: 22810476
Drug: Perianal administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Perianal administration
Trial: 22810476
Drug: Endoanal administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Endoanal administration
Trial: 19955824
Drug: Cinacalcet for
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cinacalcet for 6 months in group L (gland >=500 mm(3))
Trial: 19955824
Drug: Cinacalcet for
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cinacalcet for 6 months in both groups S and L
Trial: 15545508
Drug: COX‐2‐specific inhibitors
FDA approved: no
EMA approved: no
PMDA approved: no
Description: COX‐2‐specific inhibitors
Trial: 8767599
Drug: Physical training
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physical training + low-dose heparin calcium (12,500 IU/day for 6 months)
Trial: 1751265
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose lignocaine (mean plasma concentration 0.92 micrograms ml‐1)
Trial: 1751265
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose lignocaine (mean plasma concentration 1.78 micrograms ml‐1)
Trial: 1751265
Drug: Lignocaine (both
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lignocaine (both doses)
Trial: 26362760
Drug: Sublingual immunotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sublingual immunotherapy (SLIT) with peanut for 12 months
Trial: 25321447
Drug: Endobronchial therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endobronchial therapy (treatment group)
Trial: 20001969
Drug: GIK (glucose-insulin-potassium)
RxNorm normalized name: glucose / potassium chloride
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GIK (glucose-insulin-potassium) infusion
Trial: 18312520
Drug: Infusion injection
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Infusion injection of rocuronium (I0.6, I0.9)
Trial: 18312520
Drug: Bolus injection
RxNorm normalized name: SET,INFUSION,BOLUS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bolus injection of rocuronium (B0.6, B0.9)
Trial: 15670545
Drug: Rosuvastatin (various
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rosuvastatin (various doses)
Trial: 15670545
Drug: Atorvastatin (various
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin (various doses)
Trial: 15670545
Drug: Simvastatin (various
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simvastatin (various doses)
Trial: 15670545
Drug: Pravastatin (various
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pravastatin (various doses)
Trial: 15670545
Drug: Overall treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Overall treatment with rosuvastatin, atorvastatin, simvastatin, and pravastatin
Trial: 14746860
Drug: Cisplatin (CDDP)
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cisplatin (CDDP) at a dose of 80 mg/m(2) every 14 days for four courses, followed by delayed surgery and two more similar CDDP courses for SR-HB patients.
Trial: 14746860
Drug: Cisplatin (CDDP)
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cisplatin (CDDP) alternating every 14 days with carboplatin (CARBO), 500 mg/m(2), and doxorubicin (DOXO), 60 mg/m(2) for HR-HB patients.
Trial: 9092746
Drug: Glycolic acid
RxNorm normalized name: Glycolic Acid
DrugBank: Glycolic acid (DB03085)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Glycolic acid treatment
Trial: 9092746
Drug: Jessner's solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Jessner's solution treatment
Trial: 8250708
Drug: Cimetidine (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cimetidine (300 mg bolus followed by 37.5 mg/h)
Trial: 8250708
Drug: Sucralfate (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sucralfate (1 g every 6 hours suspended in 20 mL of sterile water)
Trial: 26762204
Drug: Bevacizumab (beva)
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Bevacizumab (beva) + CCNU chemotherapy
Trial: 22711898
Drug: Rizatriptan (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rizatriptan (5 mg for < 40 kg, 10 mg for ≥ 40 kg)
Trial: 18272093
Drug: 0.05 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.05 mg/kg morphine then 0.025 mg/kg every 5 minutes (group A)
Trial: 18272093
Drug: 0.1 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.1 mg/kg morphine then 0.05 mg/kg every 5 minutes (group B)
Trial: 12778779
Drug: Infusions taken
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Infusions taken directly from a warming box in the ambulance (Group A, n = 25)
Trial: 12778779
Drug: Infusions taken
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Infusions taken from the warming box and packed in an insulation device (Group B, n = 25)
Trial: 9704787
Drug: Fetal plasma
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fetal plasma interleukin‐6 concentrations > 11 pg/mL
Trial: 9704787
Drug: Fetal plasma
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fetal plasma interleukin‐6 concentrations ≤ 11 pg/mL
Trial: 29513248
Drug: Endoscopic sclerotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endoscopic sclerotherapy with 3-day substitution therapy of deficient factors VIII or IX
Trial: 26918279
Drug: TAS-102 (35
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAS-102 (35 mg/m²) administered in a single dose during pharmacokinetic phase and twice-daily doses in 28-day cycles during repeated administration phase.
Trial: 26918279
Drug: TAS-102 (twice-daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAS-102 (twice-daily doses) during repeated administration phase.
Trial: 26918279
Drug: TAS-102 (postprandial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAS-102 (postprandial administration).
Trial: 16463831
Drug: Magnesium sulfate
RxNorm normalized name: Magnesium Sulfate
DrugBank: Magnesium (DB14513)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Magnesium sulfate (20 mmol over 10 min followed by an infusion of 4 mmol/h)
Trial: 10398629
Drug: Montelukast (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Montelukast (10 mg tablet) once daily at bedtime for up to 12 weeks
Trial: 10398629
Drug: Placebo once
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo once daily at bedtime for up to 12 weeks
Trial: 7570431
Drug: Once weekly
RxNorm normalized name: Actonel 35 4-Week Once Weekly Dosepack
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once weekly physiotherapy (group A) after initial twice weekly sessions for 3 months
Trial: 7570431
Drug: Once monthly
RxNorm normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Once monthly physiotherapy (group B) after initial twice weekly sessions for 3 months
Trial: 2112131
Drug: 4% lidocaine
RxNorm normalized name: Lidocaine 344 mg TOPICAL PATCH [Pain Relief 4% Lidocaine]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4% lidocaine inhalation
Trial: 378094
Drug: Inderectic (propranolol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inderectic (propranolol 80 mg and bendrofluazide 2.5 mg, given twice daily)
Trial: 378094
Drug: Free combination
RxNorm normalized name: SUNSCREEN-29 PABA-FREE COMBINATION LOT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Free combination of propranolol and bendrofluazide (given as separate tablets)
Trial: 6840831
Drug: liver-solution with
RxNorm normalized name: LIVER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: liver-solution with 45% branched chain amino acids
Trial: 6840831
Drug: conventional solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: conventional solution with 10.5% branched chain amino acids
Trial: 30591575
Drug: Daily SMS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily SMS quizzes
Trial: 30591575
Drug: Daily SMS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily SMS quizzes with daily readings and online CME courses
Trial: 24506265
Drug: 4 ml
RxNorm normalized name: ethanol 1.4 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 ml 1% methylene blue and 16 ml 0.5% marcaine
Trial: 24506265
Drug: 16 ml
RxNorm normalized name: 16 ML Mvasi 25 MG/ML Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 16 ml 0.5% marcaine and 4 ml saline (placebo)
Trial: 19679221
Drug: All groups
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All groups (Glucosamine, Ibuprofen, Placebo)
Trial: 15843221
Drug: 7-oxo-dehydroepiandrosterone (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7-oxo-dehydroepiandrosterone (25 mg daily transdermally for 8 days)
Trial: 9791752
Drug: Vaccinated children
RxNorm normalized name: Pediaclear Childrens
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaccinated children (PRP-T vaccine)
Trial: 7881681
Drug: Standard physical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard physical therapy (STD)
Trial: 7881681
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of standard therapy with exercise (EX)
Trial: 2875594
Drug: Midazolam 10
RxNorm normalized name: midazolam 10 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midazolam 10 mg
Trial: 31170712
Drug: Bardoxolone methyl
RxNorm normalized name: Bardoxolone methyl
DrugBank: Bardoxolone methyl (DB05983)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bardoxolone methyl (Bard) 20 mg once daily
Trial: 23934045
Drug: 40 mg
RxNorm normalized name: rutin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg parecoxib injected intravenously 30 min before surgery and every 12 h for 2 days
Trial: 23934045
Drug: Incision-local block
RxNorm normalized name: Ivy Block
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Incision-local block with 5 ml of 0.5% ropivacaine and 20 ml of physiological saline every 12 h for 2 days
Trial: 21114583
Drug: Combined metformin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined metformin and clomiphene citrate (CC)
Trial: 20003788
Drug: Remifemin 20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remifemin 20 mg bid po for 12 weeks
Trial: 20003788
Drug: Tibolone 2.5
RxNorm normalized name: tibolone 2.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tibolone 2.5 mg qd po for 12 weeks
Trial: 15532067
Drug: Test bromazepam
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Test bromazepam formulation (6 mg)
Trial: 15532067
Drug: Reference bromazepam
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reference bromazepam formulation (6 mg)
Trial: 1315212
Drug: WR-2721 (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: WR-2721 (100 mg/enema to 450 mg/enema)
Trial: 3876591
Drug: Trimethoprim/sulphamethoxazole treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trimethoprim/sulphamethoxazole treatment in achlorhydric and postgastrectomy patients
Trial: 23965225
Drug: Subcutaneous trastuzumab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous trastuzumab (600 mg fixed-dose via single-use injection device)
Trial: 26806010
Drug: Intravenous trastuzumab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous trastuzumab
Trial: 14600686
Drug: 1.5 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.5 mg/kg of methylprednisolone sodium succinate (MP)
Trial: 14600686
Drug: 3 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 mg/kg of methylprednisolone sodium succinate (MP)
Trial: 10912539
Drug: Daily oral
RxNorm normalized name: GEMTESA 75 MG Once-Daily Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily oral calcitriol (10 ng/kg per day)
Trial: 10912539
Drug: Intermittent oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermittent oral calcitriol (35 ng/kg given twice a week)
Trial: 1550367
Drug: Isotretinoin cream
RxNorm normalized name: Isotretinoin
DrugBank: Isotretinoin (DB00982)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Isotretinoin cream (0.05% for 3 months, then 0.1% for 6 months)
Trial: 6400534
Drug: Cefsulodin in
RxNorm normalized name: cefsulodin
DrugBank: Cefsulodin (DB13499)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefsulodin in combination with a nonantipseudomonal antibiotic (9 patients)
Trial: 6400534
Drug: Cefsulodin (2-8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefsulodin (2-8 g/day) for 4-37 days (25 patients)
Trial: 6400534
Drug: Cefsulodin (4-12
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefsulodin (4-12 g/day) for 5-45 days (15 patients)
Trial: 29063703
Drug: Triamcinolone (8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triamcinolone (8 mg)
Trial: 27289365
Drug: BZP (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BZP (200 mg)
Trial: 27289365
Drug: BZP +
RxNorm normalized name: Benzylpiperazine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BZP + TFMPP (100 mg/30 mg)
Trial: 27289365
Drug: All drug
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All drug treatments
Trial: 23134924
Drug: Oral hydration
RxNorm normalized name: terpin hydrate Oral Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral hydration therapy (2 liters of water within 2 hours, then 2 liters daily for 7 days)
Trial: 23134924
Drug: Oral hydration
RxNorm normalized name: terpin hydrate Oral Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral hydration therapy
Trial: 16319109
Drug: Ramosetron (0.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ramosetron (0.3 mg i.v. bolus 30 min before cisplatin on Day 1 and a 0.1 mg tablet for Days 2 to 5)
Trial: 16319109
Drug: Granisetron (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Granisetron (3 mg i.v. infusion 30 min before cisplatin on Day 1 and a 1 mg tablet for Days 2 to 5)
Trial: 12830468
Drug: Intravenous injection
RxNorm normalized name: Meta Trace FDG, intravenous injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous injection of 300 mg ascorbic acid
Trial: 3628857
Drug: Aminoglutethimide 1000
RxNorm normalized name: Aminoglutethimide
DrugBank: Aminoglutethimide (DB00357)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aminoglutethimide 1000 mg and hydrocortisone 40 mg daily
Trial: 3628857
Drug: Aminoglutethimide 1000
RxNorm normalized name: Aminoglutethimide
DrugBank: Aminoglutethimide (DB00357)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aminoglutethimide 1000 mg, hydrocortisone 40 mg and fluoxymesterone 20 mg daily
Trial: 27423556
Drug: Clopidogrel and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clopidogrel and aspirin (dual therapy)
Trial: 25995278
Drug: Vitamin B-12
RxNorm normalized name: Vitamin B-12
DrugBank: Cyanocobalamin (DB00115)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vitamin B-12 intake of ∼8.6 μg/d (mixed diet plus prenatal multivitamin supplement)